跳轉至內容
Merck
全部照片(1)

文件

SML1391

Sigma-Aldrich

Olmesartan medoxomil

≥98% (HPLC)

同義詞:

4-(1-Hydroxy-1-methylethyl)-2-propyl-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, CS-866

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C29H30N6O6
CAS號碼:
分子量::
558.59
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

DMSO: 10 mg/mL, clear

儲存溫度

2-8°C

SMILES 字串

CCCC1=NC(C(O)(C)C)=C(C(OCC2=C(C)OC(O2)=O)=O)N1CC(C=C3)=CC=C3C4=CC=CC=C4C5=NN=NN5

InChI

1S/C29H30N6O6/c1-5-8-23-30-25(29(3,4)38)24(27(36)39-16-22-17(2)40-28(37)41-22)35(23)15-18-11-13-19(14-12-18)20-9-6-7-10-21(20)26-31-33-34-32-26/h6-7,9-14,38H,5,8,15-16H2,1-4H3,(H,31,32,33,34)

InChI 密鑰

UQGKUQLKSCSZGY-UHFFFAOYSA-N

基因資訊

human ... AGTR1(185)

尋找類似的產品? 前往 產品比較指南

生化/生理作用

Olmesartan medoxomil is a selective Angiotensin II Type I receptor blocker and antihypertensive drug. Olmesartan medoxomil is converted enzymatically to the active form olmesartan.
Olmesartan medoxomil is considered as an antihypertensive agent. It is an angiotensin 2 type 1 antagonist receptor. It is a prodrug which releases the parent compound olmesartan after ingestion. Olmesartan is ejected via kidney and liver. In humans, olmesartan protects renal and cardiovascular systems. This drug may be used in the treatment of hypertension.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Angiotensin II Inhibitors: Advances in Research and Application (2012)
Hans R Brunner
Journal of human hypertension, 16 Suppl 2, S13-S16 (2002-04-23)
The new orally active angiotensin II (A II) type-1 receptor antagonist olmesartan medoxomil is a prodrug, which is rapidly converted in vivo to the active metabolite, olmesartan. The pharmacology, antihypertensive efficacy and safety of olmesartan medoxomil and/or the pharmacologically active
Current Cardiovascular Drugs (2005)
Case Studies in Modern Drug Discovery and Development (2012)
Linear mixed-effects model of QTc prolongation for olmesartan medoxomil.
SaeHeum Song et al.
Journal of clinical pharmacology, 56(1), 96-100 (2015-06-23)

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務